{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:26:58Z","timestamp":1773804418582,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["0098\/2021\/A2"],"award-info":[{"award-number":["0098\/2021\/A2"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["0048\/2023\/AFJ"],"award-info":[{"award-number":["0048\/2023\/AFJ"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015249","name":"State Key Laboratory of Quality Research in Chinese Medicine, University of Macau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015249","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioactive Materials"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bioactmat.2025.11.004","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T17:13:11Z","timestamp":1763399591000},"page":"267-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Biomimetic universal CAR-mesenchymal stem cell nanohybrids for anti-tumor therapy"],"prefix":"10.1016","volume":"57","author":[{"given":"Lang-Yu","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Li","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-Biao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing-Xing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bioactmat.2025.11.004_bib1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential cd19-22 car t therapy induces sustained remission in children with r\/r b-all","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bioactmat.2025.11.004_bib2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjh.18335","article-title":"Chimeric antigen receptor t-cell therapy is superior to standard of care as second-line therapy for large b-cell lymphoma: a systematic review and meta-analysis","volume":"198","author":"Shargian","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.bioactmat.2025.11.004_bib3","first-page":"372","article-title":"Mechanisms of resistance to car t cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bioactmat.2025.11.004_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001619","article-title":"Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy","volume":"8","author":"Wang","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.bioactmat.2025.11.004_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/imm.12976","article-title":"Macrophage targeting: opening new possibilities for cancer immunotherapy","volume":"155","author":"Cassetta","year":"2018","journal-title":"Immunology"},{"issue":"22","key":"10.1016\/j.bioactmat.2025.11.004_bib6","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1182\/bloodadvances.2020002547","article-title":"Next-generation cell therapies: the emerging role of car-nk cells","volume":"4","author":"Basar","year":"2020","journal-title":"Blood Adv."},{"issue":"19","key":"10.1016\/j.bioactmat.2025.11.004_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202308377","article-title":"Enhancing car macrophage efferocytosis via surface engineered lipid nanoparticles targeting lxr signaling","volume":"36","author":"Chuang","year":"2024","journal-title":"Adv. Mater."},{"issue":"6","key":"10.1016\/j.bioactmat.2025.11.004_bib8","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"9","key":"10.1016\/j.bioactmat.2025.11.004_bib9","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nri2395","article-title":"Mesenchymal stem cells in health and disease","volume":"8","author":"Uccelli","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.11.004_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in aml","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.bioactmat.2025.11.004_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000349","article-title":"Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells","volume":"2","author":"Saito","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.11.004_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","article-title":"Car-t cells targeting cll-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.11.004_bib13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase i study of cll-1 car-t cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.bioactmat.2025.11.004_bib14","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1021\/acsnano.0c00708","article-title":"Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma","volume":"14","author":"Yu","year":"2020","journal-title":"ACS Nano"},{"issue":"40","key":"10.1016\/j.bioactmat.2025.11.004_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202307706","article-title":"Sodium bicarbonate nanoparticles for amplified cancer immunotherapy by inducing pyroptosis and regulating lactic acid metabolism","volume":"62","author":"Ding","year":"2023","journal-title":"Angew. Chem. Int. Ed."},{"issue":"9","key":"10.1016\/j.bioactmat.2025.11.004_bib16","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/s43018-020-0095-6","article-title":"Multifunctional oncolytic nanoparticles deliver self-replicating il-12 rna to eliminate established tumors and prime systemic immunity","volume":"1","author":"Li","year":"2020","journal-title":"Nat. Cancer"},{"issue":"2","key":"10.1016\/j.bioactmat.2025.11.004_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.bioactmat.2025.11.004_bib18","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.7150\/thno.112475","article-title":"Nano drug delivery systems for advanced immune checkpoint blockade therapy","volume":"15","author":"Guo","year":"2025","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.bioactmat.2025.11.004_bib19","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1016\/j.apsb.2024.03.010","article-title":"Dendritic nanomedicine enhances chemo-immunotherapy by disturbing metabolism of cancer-associated fibroblasts for deep penetration and activating function of immune cells","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"15","key":"10.1016\/j.bioactmat.2025.11.004_bib20","doi-asserted-by":"crossref","first-page":"18411","DOI":"10.1021\/acsami.3c18497","article-title":"Fepd nanozyme- and skn-encapsulated functional lipid nanoparticles for cancer nanotherapy via ros-boosting necroptosis","volume":"16","author":"Xie","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.bioactmat.2025.11.004_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/imr.12583","article-title":"Necroptotic cell death in anti-cancer therapy","volume":"280","author":"Krysko","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bioactmat.2025.11.004_bib22","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jconrel.2022.01.015","article-title":"Codelivery of shikonin and sitgf-\u03b2 for enhanced triple negative breast cancer chemo-immunotherapy","volume":"342","author":"Li","year":"2022","journal-title":"J. Contr. Release"},{"issue":"5","key":"10.1016\/j.bioactmat.2025.11.004_bib23","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1021\/acs.nanolett.9b00021","article-title":"Reprogramming tumor immune microenvironment (time) and metabolism via biomimetic targeting codelivery of shikonin\/jq1","volume":"19","author":"Wang","year":"2019","journal-title":"Nano Lett."},{"issue":"7519","key":"10.1016\/j.bioactmat.2025.11.004_bib24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.bioactmat.2025.11.004_bib25","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1158\/0008-5472.CAN-18-1367","article-title":"Diverse functions of macrophages in different tumor microenvironments","volume":"78","author":"Yang","year":"2018","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.11.004_bib26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41392-021-00631-2","article-title":"Recent progress in targeted delivery vectors based on biomimetic nanoparticles","volume":"6","author":"Chen","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"3","key":"10.1016\/j.bioactmat.2025.11.004_bib27","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1021\/acs.nanolett.9b04683","article-title":"Charge conversional biomimetic nanocomplexes as a multifunctional platform for boosting orthotopic glioblastoma rnai therapy","volume":"20","author":"Liu","year":"2020","journal-title":"Nano Lett."},{"issue":"51","key":"10.1016\/j.bioactmat.2025.11.004_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201803717","article-title":"Effective and targeted human orthotopic glioblastoma xenograft therapy via a multifunctional biomimetic nanomedicine","volume":"30","author":"Zou","year":"2018","journal-title":"Adv. Mater."},{"issue":"43","key":"10.1016\/j.bioactmat.2025.11.004_bib29","doi-asserted-by":"crossref","first-page":"9581","DOI":"10.1002\/adma.201602173","article-title":"Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors","volume":"28","author":"Sun","year":"2016","journal-title":"Adv. Mater."},{"issue":"23","key":"10.1016\/j.bioactmat.2025.11.004_bib30","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1002\/anie.201903475","article-title":"Metal\u2013organic framework (mof) hybrid as a tandem catalyst for enhanced therapy against hypoxic tumor cells","volume":"58","author":"Liu","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bioactmat.2025.11.004_bib31","first-page":"299","article-title":"A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-pd-l1 antibody","volume":"21","author":"Li","year":"2023","journal-title":"Bioact. Mater."},{"issue":"1","key":"10.1016\/j.bioactmat.2025.11.004_bib32","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1021\/acsnano.1c08619","article-title":"Nanotransferrin-based programmable catalysis mediates three-pronged induction of oxidative stress to enhance cancer immunotherapy","volume":"16","author":"Bai","year":"2022","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.bioactmat.2025.11.004_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202006484","article-title":"Immune cell membrane-coated biomimetic nanoparticles for targeted cancer therapy","volume":"17","author":"Oroojalian","year":"2021","journal-title":"Small"},{"issue":"42","key":"10.1016\/j.bioactmat.2025.11.004_bib34","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1038\/onc.2011.137","article-title":"Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2","volume":"30","author":"Chen","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.bioactmat.2025.11.004_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104463","article-title":"Pharmacological properties and derivatives of shikonin-A review in recent years","volume":"149","author":"Guo","year":"2019","journal-title":"Pharmacol. Res."}],"container-title":["Bioactive Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X25005250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452199X25005250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:21:37Z","timestamp":1773800497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452199X25005250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"alternative-id":["S2452199X25005250"],"URL":"https:\/\/doi.org\/10.1016\/j.bioactmat.2025.11.004","relation":{},"ISSN":["2452-199X"],"issn-type":[{"value":"2452-199X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomimetic universal CAR-mesenchymal stem cell nanohybrids for anti-tumor therapy","name":"articletitle","label":"Article Title"},{"value":"Bioactive Materials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioactmat.2025.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}